ABSTRACT
Since their discovery over 35 years ago, liposomes have been applied to the delivery of a wide range of drugs by virtually every route of administration [1,2]. This chapter will discuss intravenous (IV) liposomes that use Stealth technology to target their contents to specific sites of disease. Particular attention will be paid to Doxil (doxorubicin HCl liposome injection), also known as Caelyx in countries outside the United States.
